- Home
- VIRX vs NRXP Comparison
VIRX vs NRXP Comparison
Compare VIRX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIRX
- NRXP
- Stock Information
- Founded
- VIRX 2007
- NRXP 2015
- Country
- VIRX United States
- NRXP United States
- Employees
- VIRX N/A
- NRXP N/A
- Industry
- VIRX Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- VIRX Health Care
- NRXP Health Care
- Exchange
- VIRX Nasdaq
- NRXP Nasdaq
- Market Cap
- VIRX 8.8M
- NRXP 14.8M
- IPO Year
- VIRX N/A
- NRXP N/A
- Fundamental
- Price
- VIRX $0.22
- NRXP $1.27
- Analyst Decision
- VIRX Buy
- NRXP Strong Buy
- Analyst Count
- VIRX 4
- NRXP 2
- Target Price
- VIRX $5.50
- NRXP $31.50
- AVG Volume (30 Days)
- VIRX 146.3K
- NRXP 92.6K
- Earning Date
- VIRX 11-07-2024
- NRXP 11-12-2024
- Dividend Yield
- VIRX N/A
- NRXP N/A
- EPS Growth
- VIRX N/A
- NRXP N/A
- EPS
- VIRX N/A
- NRXP N/A
- Revenue
- VIRX N/A
- NRXP N/A
- Revenue This Year
- VIRX N/A
- NRXP N/A
- Revenue Next Year
- VIRX N/A
- NRXP N/A
- P/E Ratio
- VIRX N/A
- NRXP N/A
- Revenue Growth
- VIRX N/A
- NRXP N/A
- 52 Week Low
- VIRX $0.20
- NRXP $1.10
- 52 Week High
- VIRX $1.31
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- VIRX 37.72
- NRXP 28.93
- Support Level
- VIRX $0.20
- NRXP $1.10
- Resistance Level
- VIRX $0.24
- NRXP $1.44
- Average True Range (ATR)
- VIRX 0.01
- NRXP 0.11
- MACD
- VIRX 0.00
- NRXP -0.02
- Stochastic Oscillator
- VIRX 32.00
- NRXP 23.57
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.